CPT1A and alveolar rhabdomyosarcoma: Future efforts should be directed to better understand the molecular mechanism responsible for CPT1A-mediated cell motility, in order to facilitate the full validation of CPT1A as a novel therapeutic target for the treatment of ARMS.